Contact

Background

Background

Neuroimmune diseases include multiple sclerosis (MS), neuromyelitis optica spectrum disease (NMOSD), autoimmune encephalitis (AE), Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), myasthenia gravis (MG), Guillain-Barre syndrome (GBS), inflammatory peripheral neurological diseases, etc. The cause of these diseases is unclear. The pathological mechanism is that the T cells and B cells that mediate the immune system mistakenly attack the central or peripheral nerve tissue and receptors in neuromuscular dissemination as an external antigen, resulting in immune-mediated pathological damage and nerve or muscles and other tissues. Neuroimmune diseases are the main reason for young adult disability. Clinical manifestations are complex and diverse. The choice of treatment and adjustment requires experienced experts. Early and correct diagnosis, monitoring of disease progression, and drug efficacy mainly depend on the detection of fluid biomarkers, including antigen, antibody, and trace nerve tissue protein.

Originate

In 2010, under the leadership of Professors Fu-Dong Shi and Li Yang, the Neurology Department of Tianjin Medical University General Hospital established a specialized outpatient and ward for the diagnosis, treatment, and long-term management of neuroimmune diseases. It took the lead in using disease-modifying drugs in China and accumulated rich experience. In 2018, Beijing Tiantan Hospital and China National Clinical Research Center for Neurological Diseases were relocated to Fengtai district of Beijing. Professor Fu-Dong Shi integrated the neuroimmunology teams and streamlined clinical service and research both Tianjin Medical University General Hospital and Beijing Tiantan Hospital, thus laid foundation for Jing-Jin Center for Neuroinflammation, expanding the patient's service to national and international patients.

Tianjin New Terrain Biotechnology Co., Ltd. (New Terrain), born in 2018, is a product of the expanding clinical service demand from Jing-Jin Center for Neuroinflammation and national initiatives for technology independence.

Based on the innovations of our team for more than ten years, we are committed to

Developing laboratory diagnostic reagents for neuroinflammatory diseases, and expanding the neurological biomarker detection array for diagnosis, progress, curative effect prediction;

Screening new fluid biomarkers for early diagnosis, progress and prognosis evaluation of neurodegenerative diseases such as cognitive disorders and movement disorders;

Pre-clinical and clinical trial services;

Develop new immunomodulatory drugs for single or combinational treatment of neurological diseases.

In the three years since the establishment of New Terrain, the R&D department has been determined to forge ahead, the technology has been continuously upgraded, and the product pipeline and intellectual property rights have been enriched.

At present, the company has reached strategic cooperation with KingMed Diagnostics, the largest third-party medical laboratory in China, and has gradually formed an integrated model of national laboratory diagnosis and clinical information services.

Our Team